Sales Support
U.S.:+1-415-871-0703
U.K.:+44-203-289-4040
AUS.: +61-2-4786-0457
INDIA:+91-848-285-0837
Contact Us
We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
Services industry

Non Small Cell Lung Cancer Drugs Market 2020 By Manufacturers, Regions, Types, Applications And Forecast To 2026

  • Code : SMI27170
  • Pages : 92
  • Date : Aug, 2020
  • Category : Services
  • Publisher : SMI
  • Format : SMI PPT FormatSMI PDF Format

  • Purchase Options

 

Summary

The global Non Small Cell Lung Cancer Drugs Market is expected to witness a CAGR of xx% over the forecast period 2020-2026 and is expected to reach US$ xx million in 2026, from US$ xx million in 2019. 

Lung cancer is a type of non-small cell lung cancer. There are different types of non-small cell lung cancer therapy that a doctor can recommend. Surgery is an option in some cases, and depending on what stage the patient is in, they can either be removed surgically or treated with radiation and chemotherapy. Chemotherapy is a highly effective way to kill off cancerous cells. Most lung cancers can be treated with this form of therapy.

The increasing prevalence of non-small cell lung cancer is propelling the growth of the non-small cell lung cancer drugs market. According to the report published by Medscape, non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and is divided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The presence of a strong pipeline for NSCLC drugs coupled with the increasing geographical penetration is again anticipated to augment the globe. Moreover, increasing spending on the healthcare industry, and availability of advanced drugs, and a large patient pool is further projected to accelerate the growth of the non-small cell lung cancer drugs market.

North America is projected to exhibit significant growth over the forecast period and this is attributed to the increasing spending on cancer treatment in the region. According to the National Cancer Institute, estimated national expenditures for cancer care in the United States in 2018 were $150.8 billion. In future years, costs are likely to increase as the population ages and more people have cancer.

Key Developments:

  1. In April 2018, Global pharma major Roche announced the launch of monoclonal antibody atezolizumab under the brand name Tecentriq in India for treatment of lung and bladder cancer
  2. In May 2020, Novartis announced that the US Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib, formerly INC280), an oral MET inhibitor for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test
  3. In December 2020, Amgen announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sotorasib, an investigational KRASG12C inhibitor for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)
  4. In June 2020, The FDA approved 2 new therapies, Atezolizumab and Nivolumab each with its own companion diagnostic for the treatment of patients with metastatic non–small cell lung cancer.

The Non Small Cell Lung Cancer Drugs Market report highlights product development and growth strategies such as merger and acquisition adopted by market players along with SWOT Analysis, PEST and Porter’s Five Forces analyses of the Non Small Cell Lung Cancer Drugs Market, which highlight the strengths, weaknesses, opportunities, and commination of key companies. Moreover, the report offers two distinct market forecasts, one from the perspective of the producer and another from that of the consumer.

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.

The Key Manufacturers covered in this Report:-

  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • ...

By the Product Type, the market is primarily segmented into:

  • Biologics
  • Small Molecule Targeted Therapy
  • Chemotherapy
  • Other

By Applications, the market is segmented into:

  • Lung Adenocarcinoma
  • Squamous Cell Lung Carcinoma
  • Large-cell Lung Carcinoma

The Report covers the following Regions:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Philippines
    • Vietnam
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Central & South America
    • Brazil
  • Middle East & Africa
    • Turkey
    • GCC Countries
    • Egypt
    • South Africa

Objective of the Non Small Cell Lung Cancer Drugs Market Report:

  • To assess the size of the market by value and volume
  • Analyze the Non Small Cell Lung Cancer Drugs Market in terms of regions and major countries
  • Highlight recent developments and trends in the market
  • Offer perceptive data regarding major market players in terms of key developments, strategies, and product portfolio
  • Determine share of the Non Small Cell Lung Cancer Drugs Market in terms of various segments such as by product type, application, and end-user
  • Offer accurate projection of the market for the forecast period using state-of –the-art tools and the current primary and secondary research approaches
  • Discuss major factors that impact growth of the Non Small Cell Lung Cancer Drugs Market

The Non Small Cell Lung Cancer Drugs Market engages the readers with all pivotal approaches to understand their position in the industry based on revenue or sales growth. The report efficiently evaluates the Non Small Cell Lung Cancer Drugs Market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competition in the market. The information in the report is backed by annual company reports, financial reports, press releases, regulatory databases, government documents, and statistical databases.

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders:

  • Material suppliers/wholesalers
  • Market Distributors/traders
  • Regulatory bodies
  • Research organizations, and consulting firms
  • Commercial research & developments (R&D)
  • Trade associations and industry bodies
  • Importers and exporters
  • End-use industries

Available Customizations:

Custom research is one of the most crucial components of the business strategy that helps an organization gain insight into specific business sector, aligned with its specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-small Cell Lung Cancer Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global Non-small Cell Lung Cancer Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Biologics
1.4.3 Small Molecule Targeted Therapy
1.4.4 Chemotherapy
1.4.5 Other
1.5 Market by Application
1.5.1 Global Non-small Cell Lung Cancer Drugs Market Share by Application: 2020 VS 2026
1.5.2 Lung Adenocarcinoma
1.5.3 Squamous Cell Lung Carcinoma
1.5.4 Large-cell Lung Carcinoma
1.6 Coronavirus Disease 2019 (Covid-19): Non-small Cell Lung Cancer Drugs Industry Impact
1.6.1 How the Covid-19 is Affecting the Non-small Cell Lung Cancer Drugs Industry
1.6.1.1 Non-small Cell Lung Cancer Drugs Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Non-small Cell Lung Cancer Drugs Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Non-small Cell Lung Cancer Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 Global Growth Trends by Regions
2.1 Non-small Cell Lung Cancer Drugs Market Perspective (2015-2026)
2.2 Non-small Cell Lung Cancer Drugs Growth Trends by Regions
2.2.1 Non-small Cell Lung Cancer Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Non-small Cell Lung Cancer Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Non-small Cell Lung Cancer Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porters Five Forces Analysis
2.3.5 Non-small Cell Lung Cancer Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Non-small Cell Lung Cancer Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Non-small Cell Lung Cancer Drugs Players by Market Size
3.1.1 Global Top Non-small Cell Lung Cancer Drugs Players by Revenue (2015-2020)
3.1.2 Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Non-small Cell Lung Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Non-small Cell Lung Cancer Drugs Market Concentration Ratio
3.2.1 Global Non-small Cell Lung Cancer Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Non-small Cell Lung Cancer Drugs Revenue in 2019
3.3 Non-small Cell Lung Cancer Drugs Key Players Head office and Area Served
3.4 Key Players Non-small Cell Lung Cancer Drugs Product Solution and Service
3.5 Date of Enter into Non-small Cell Lung Cancer Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)
4.1 Global Non-small Cell Lung Cancer Drugs Historic Market Size by Type (2015-2020)
4.2 Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Type (2021-2026)

5 Non-small Cell Lung Cancer Drugs Breakdown Data by Application (2015-2026)
5.1 Global Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)
5.2 Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Non-small Cell Lung Cancer Drugs Market Size (2015-2020)
6.2 Non-small Cell Lung Cancer Drugs Key Players in North America (2019-2020)
6.3 North America Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020)
6.4 North America Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)

7 Europe
7.1 Europe Non-small Cell Lung Cancer Drugs Market Size (2015-2020)
7.2 Non-small Cell Lung Cancer Drugs Key Players in Europe (2019-2020)
7.3 Europe Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020)
7.4 Europe Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)

8 China
8.1 China Non-small Cell Lung Cancer Drugs Market Size (2015-2020)
8.2 Non-small Cell Lung Cancer Drugs Key Players in China (2019-2020)
8.3 China Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020)
8.4 China Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)

9 Japan
9.1 Japan Non-small Cell Lung Cancer Drugs Market Size (2015-2020)
9.2 Non-small Cell Lung Cancer Drugs Key Players in Japan (2019-2020)
9.3 Japan Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020)
9.4 Japan Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size (2015-2020)
10.2 Non-small Cell Lung Cancer Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)

11 India
11.1 India Non-small Cell Lung Cancer Drugs Market Size (2015-2020)
11.2 Non-small Cell Lung Cancer Drugs Key Players in India (2019-2020)
11.3 India Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020)
11.4 India Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Non-small Cell Lung Cancer Drugs Market Size (2015-2020)
12.2 Non-small Cell Lung Cancer Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020)
12.4 Central & South America Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 AstraZeneca
13.1.1 AstraZeneca Company Details
13.1.2 AstraZeneca Business Overview and Its Total Revenue
13.1.3 AstraZeneca Non-small Cell Lung Cancer Drugs Introduction
13.1.4 AstraZeneca Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020))
13.1.5 AstraZeneca Recent Development
13.2 Bristol-Myers Squibb Company
13.2.1 Bristol-Myers Squibb Company Company Details
13.2.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
13.2.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Introduction
13.2.4 Bristol-Myers Squibb Company Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020)
13.2.5 Bristol-Myers Squibb Company Recent Development
13.3 Eli Lilly and Company
13.3.1 Eli Lilly and Company Company Details
13.3.2 Eli Lilly and Company Business Overview and Its Total Revenue
13.3.3 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Introduction
13.3.4 Eli Lilly and Company Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020)
13.3.5 Eli Lilly and Company Recent Development
13.4 F. Hoffmann-La Roche Ltd
13.4.1 F. Hoffmann-La Roche Ltd Company Details
13.4.2 F. Hoffmann-La Roche Ltd Business Overview and Its Total Revenue
13.4.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Introduction
13.4.4 F. Hoffmann-La Roche Ltd Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020)
13.4.5 F. Hoffmann-La Roche Ltd Recent Development
13.5 Merck & Co., Inc.
13.5.1 Merck & Co., Inc. Company Details
13.5.2 Merck & Co., Inc. Business Overview and Its Total Revenue
13.5.3 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Introduction
13.5.4 Merck & Co., Inc. Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020)
13.5.5 Merck & Co., Inc. Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Table
List of Tables
Table 1. Non-small Cell Lung Cancer Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Non-small Cell Lung Cancer Drugs Revenue
Table 3. Ranking of Global Top Non-small Cell Lung Cancer Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Non-small Cell Lung Cancer Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Biologics
Table 6. Key Players of Small Molecule Targeted Therapy
Table 7. Key Players of Chemotherapy
Table 8. Key Players of Other
Table 9. COVID-19 Impact Global Market: (Four Non-small Cell Lung Cancer Drugs Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Non-small Cell Lung Cancer Drugs Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Non-small Cell Lung Cancer Drugs Players to Combat Covid-19 Impact
Table 14. Global Non-small Cell Lung Cancer Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Non-small Cell Lung Cancer Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Non-small Cell Lung Cancer Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Non-small Cell Lung Cancer Drugs Market Share by Regions (2015-2020)
Table 18. Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Non-small Cell Lung Cancer Drugs Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Non-small Cell Lung Cancer Drugs Market Growth Strategy
Table 24. Main Points Interviewed from Key Non-small Cell Lung Cancer Drugs Players
Table 25. Global Non-small Cell Lung Cancer Drugs Revenue by Players (2015-2020) (Million US$)
Table 26. Global Non-small Cell Lung Cancer Drugs Market Share by Players (2015-2020)
Table 27. Global Top Non-small Cell Lung Cancer Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-small Cell Lung Cancer Drugs as of 2019)
Table 28. Global Non-small Cell Lung Cancer Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Non-small Cell Lung Cancer Drugs Product Solution and Service
Table 31. Date of Enter into Non-small Cell Lung Cancer Drugs Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$)
Table 34. Global Non-small Cell Lung Cancer Drugs Market Size Share by Type (2015-2020)
Table 35. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Type (2021-2026)
Table 36. Global Non-small Cell Lung Cancer Drugs Market Size Share by Application (2015-2020)
Table 37. Global Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$)
Table 38. Global Non-small Cell Lung Cancer Drugs Market Size Share by Application (2021-2026)
Table 39. North America Key Players Non-small Cell Lung Cancer Drugs Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Non-small Cell Lung Cancer Drugs Market Share (2019-2020)
Table 41. North America Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$)
Table 42. North America Non-small Cell Lung Cancer Drugs Market Share by Type (2015-2020)
Table 43. North America Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$)
Table 44. North America Non-small Cell Lung Cancer Drugs Market Share by Application (2015-2020)
Table 45. Europe Key Players Non-small Cell Lung Cancer Drugs Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Non-small Cell Lung Cancer Drugs Market Share (2019-2020)
Table 47. Europe Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Non-small Cell Lung Cancer Drugs Market Share by Type (2015-2020)
Table 49. Europe Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Non-small Cell Lung Cancer Drugs Market Share by Application (2015-2020)
Table 51. China Key Players Non-small Cell Lung Cancer Drugs Revenue (2019-2020) (Million US$)
Table 52. China Key Players Non-small Cell Lung Cancer Drugs Market Share (2019-2020)
Table 53. China Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$)
Table 54. China Non-small Cell Lung Cancer Drugs Market Share by Type (2015-2020)
Table 55. China Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$)
Table 56. China Non-small Cell Lung Cancer Drugs Market Share by Application (2015-2020)
Table 57. Japan Key Players Non-small Cell Lung Cancer Drugs Revenue (2019-2020) (Million US$)
Table 58. Japan Key Players Non-small Cell Lung Cancer Drugs Market Share (2019-2020)
Table 59. Japan Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$)
Table 60. Japan Non-small Cell Lung Cancer Drugs Market Share by Type (2015-2020)
Table 61. Japan Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$)
Table 62. Japan Non-small Cell Lung Cancer Drugs Market Share by Application (2015-2020)
Table 63. Southeast Asia Key Players Non-small Cell Lung Cancer Drugs Revenue (2019-2020) (Million US$)
Table 64. Southeast Asia Key Players Non-small Cell Lung Cancer Drugs Market Share (2019-2020)
Table 65. Southeast Asia Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$)
Table 66. Southeast Asia Non-small Cell Lung Cancer Drugs Market Share by Type (2015-2020)
Table 67. Southeast Asia Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$)
Table 68. Southeast Asia Non-small Cell Lung Cancer Drugs Market Share by Application (2015-2020)
Table 69. India Key Players Non-small Cell Lung Cancer Drugs Revenue (2019-2020) (Million US$)
Table 70. India Key Players Non-small Cell Lung Cancer Drugs Market Share (2019-2020)
Table 71. India Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$)
Table 72. India Non-small Cell Lung Cancer Drugs Market Share by Type (2015-2020)
Table 73. India Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$)
Table 74. India Non-small Cell Lung Cancer Drugs Market Share by Application (2015-2020)
Table 75. Central & South America Key Players Non-small Cell Lung Cancer Drugs Revenue (2019-2020) (Million US$)
Table 76. Central & South America Key Players Non-small Cell Lung Cancer Drugs Market Share (2019-2020)
Table 77. Central & South America Non-small Cell Lung Cancer Drugs Market Size by Type (2015-2020) (Million US$)
Table 78. Central & South America Non-small Cell Lung Cancer Drugs Market Share by Type (2015-2020)
Table 79. Central & South America Non-small Cell Lung Cancer Drugs Market Size by Application (2015-2020) (Million US$)
Table 80. Central & South America Non-small Cell Lung Cancer Drugs Market Share by Application (2015-2020)
Table 81. AstraZeneca Company Details
Table 82. AstraZeneca Business Overview
Table 83. AstraZeneca Product
Table 84. AstraZeneca Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020) (Million US$)
Table 85. AstraZeneca Recent Development
Table 86. Bristol-Myers Squibb Company Company Details
Table 87. Bristol-Myers Squibb Company Business Overview
Table 88. Bristol-Myers Squibb Company Product
Table 89. Bristol-Myers Squibb Company Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020) (Million US$)
Table 90. Bristol-Myers Squibb Company Recent Development
Table 91. Eli Lilly and Company Company Details
Table 92. Eli Lilly and Company Business Overview
Table 93. Eli Lilly and Company Product
Table 94. Eli Lilly and Company Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020) (Million US$)
Table 95. Eli Lilly and Company Recent Development
Table 96. F. Hoffmann-La Roche Ltd Company Details
Table 97. F. Hoffmann-La Roche Ltd Business Overview
Table 98. F. Hoffmann-La Roche Ltd Product
Table 99. F. Hoffmann-La Roche Ltd Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020) (Million US$)
Table 100. F. Hoffmann-La Roche Ltd Recent Development
Table 101. Merck & Co., Inc. Company Details
Table 102. Merck & Co., Inc. Business Overview
Table 103. Merck & Co., Inc. Product
Table 104. Merck & Co., Inc. Revenue in Non-small Cell Lung Cancer Drugs Business (2015-2020) (Million US$)
Table 105. Merck & Co., Inc. Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-small Cell Lung Cancer Drugs Market Share by Type: 2020 VS 2026
Figure 2. Biologics Features
Figure 3. Small Molecule Targeted Therapy Features
Figure 4. Chemotherapy Features
Figure 5. Other Features
Figure 6. Global Non-small Cell Lung Cancer Drugs Market Share by Application: 2020 VS 2026
Figure 7. Lung Adenocarcinoma Case Studies
Figure 8. Squamous Cell Lung Carcinoma Case Studies
Figure 9. Large-cell Lung Carcinoma Case Studies
Figure 10. Non-small Cell Lung Cancer Drugs Report Years Considered
Figure 11. Global Non-small Cell Lung Cancer Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Non-small Cell Lung Cancer Drugs Market Share by Regions: 2020 VS 2026
Figure 13. Global Non-small Cell Lung Cancer Drugs Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Non-small Cell Lung Cancer Drugs Market Share by Players in 2019
Figure 16. Global Top Non-small Cell Lung Cancer Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-small Cell Lung Cancer Drugs as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Non-small Cell Lung Cancer Drugs Revenue in 2019
Figure 18. North America Non-small Cell Lung Cancer Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Non-small Cell Lung Cancer Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Non-small Cell Lung Cancer Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Non-small Cell Lung Cancer Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Non-small Cell Lung Cancer Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Non-small Cell Lung Cancer Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Non-small Cell Lung Cancer Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. AstraZeneca Revenue Growth Rate in Non-small Cell Lung Cancer Drugs Business (2015-2020)
Figure 27. Bristol-Myers Squibb Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Bristol-Myers Squibb Company Revenue Growth Rate in Non-small Cell Lung Cancer Drugs Business (2015-2020)
Figure 29. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Eli Lilly and Company Revenue Growth Rate in Non-small Cell Lung Cancer Drugs Business (2015-2020)
Figure 31. F. Hoffmann-La Roche Ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Non-small Cell Lung Cancer Drugs Business (2015-2020)
Figure 33. Merck & Co., Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Merck & Co., Inc. Revenue Growth Rate in Non-small Cell Lung Cancer Drugs Business (2015-2020)
Figure 35. Bottom-up and Top-down Approaches for This Report
Figure 36. Data Triangulation
Figure 37. Key Executives Interviewed

 

  • Purchase Options

  • Happy To Assist You

Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by Types, Applications, Technology, End-use Industries, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.

Contact us